“Real world” outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the “rete ematologica pugliese”
- 22 December 2014
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 39 (3) , 279-283
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myelomaLeukemia, 2011
- Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and DexamethasoneClinical Lymphoma Myeloma and Leukemia, 2011
- Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myelomaHaematologica, 2010
- Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myelomaEuropean Journal of Haematology, 2009
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North AmericaNew England Journal of Medicine, 2007
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2007